Return to homepagePandemic Pact

Ivermectin as an anti-viral against SARS-CoV-2

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85468

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $237,676.5

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    Monash University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

We have shown that the drug Ivermectin, which is already used in humans to treat a number of parasite infections, is also very effective at preventing the virus that causes COVID-19 from replicating. We have shown this in virus infecting cells in a laboratory and now we will confirm whether it is able to be used in people suffering from COVID-19. As ivermectin is already safe for use, if it is effective against the virus at these safe concentrations it can be rapidly moved into human trials.